Review
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2023; 29(3): 450-468
Published online Jan 21, 2023. doi: 10.3748/wjg.v29.i3.450
Seronegative spondyloarthropathy-associated inflammatory bowel disease
Chrong-Reen Wang, Hung-Wen Tsai
Chrong-Reen Wang, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan 70403, Taiwan
Hung-Wen Tsai, Department of Pathology, National Cheng Kung University Hospital, Tainan 70403, Taiwan
Author contributions: Wang CR designed the report; Wang CR and Tsai HW wrote the paper, collected the clinical data, and analyzed pathological specimens.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chrong-Reen Wang, MD, PhD, Full Professor, Internal Medicine, National Cheng Kung University Hospital, No. 138 Sheng-Li Road, Tainan 70403, Taiwan. wangcr@mail.ncku.edu.tw
Received: September 30, 2022
Peer-review started: September 30, 2022
First decision: November 17, 2022
Revised: November 18, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 21, 2023
Core Tip

Core Tip: Seronegative spondyloarthropathy (SpA) with negative rheumatoid factor has spinal and peripheral arthritis, dactylitis, enthesitis and extra-articular manifestations (EAMs). It can be classified into ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, and juvenile-onset spondyloarthritis. Inflammatory bowel disease (IBD) is a common EAM in SpA, whereas extraintestinal manifestations in IBD mostly affect the joints. Anti-tumor necrosis factor monoclonal antibodies are effective medications with indicated use in SpA and IBD, a drug of choice for treating SpA-associated IBD. A tight collaboration between gastroenterologists and rheumatologists with mutual referral from early accurate diagnosis to prompt therapy is required in this complex clinical scenario.